Alzinova Past Earnings Performance
Past criteria checks 0/6
Alzinova's earnings have been declining at an average annual rate of -27.1%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 17.3% per year.
Key information
-27.1%
Earnings growth rate
9.0%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 17.3% |
| Return on equity | -14.5% |
| Net Margin | -82.9% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Alzinova makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 20 | -16 | 36 | 0 |
| 30 Sep 23 | 17 | -16 | 34 | 0 |
| 30 Jun 23 | 17 | -16 | 33 | 0 |
| 31 Mar 23 | 14 | -15 | 29 | 0 |
| 31 Dec 22 | 17 | -13 | 30 | 0 |
| 30 Sep 22 | 16 | -11 | 27 | 0 |
| 30 Jun 22 | 15 | -9 | 25 | 0 |
| 31 Mar 22 | 17 | -8 | 26 | 0 |
| 31 Dec 21 | 17 | -8 | 25 | 0 |
| 30 Sep 21 | 18 | -7 | 26 | 0 |
| 30 Jun 21 | 19 | -7 | 26 | 0 |
| 31 Mar 21 | 16 | -6 | 22 | 0 |
| 31 Dec 20 | 15 | -6 | 21 | 0 |
| 30 Sep 20 | 13 | -7 | 20 | 0 |
| 30 Jun 20 | 12 | -6 | 18 | 0 |
| 31 Mar 20 | 11 | -7 | 18 | 0 |
| 31 Dec 19 | 7 | -6 | 13 | 0 |
| 30 Sep 19 | 5 | -5 | 10 | 0 |
| 30 Jun 19 | 6 | -5 | 12 | 0 |
| 31 Mar 19 | 8 | -5 | 13 | 0 |
| 31 Dec 18 | 9 | -4 | 14 | 0 |
| 30 Sep 18 | 11 | -3 | 14 | 0 |
| 30 Jun 18 | 10 | -3 | 13 | 0 |
| 31 Mar 18 | 8 | -2 | 11 | 0 |
| 31 Dec 17 | 6 | -3 | 8 | 0 |
| 30 Sep 17 | 5 | -3 | 8 | 0 |
| 30 Jun 17 | 4 | -3 | 8 | 0 |
| 31 Mar 17 | 5 | -4 | 8 | 0 |
| 31 Dec 16 | 5 | -3 | 8 | 0 |
| 30 Sep 16 | 5 | -4 | 8 | 0 |
| 30 Jun 16 | 4 | -4 | 7 | 0 |
| 31 Mar 16 | 2 | -3 | 6 | 0 |
| 31 Dec 15 | 1 | -3 | 4 | 0 |
| 31 Dec 14 | 1 | 0 | 1 | 0 |
| 31 Dec 13 | 1 | 0 | 1 | 0 |
Quality Earnings: ALZ is currently unprofitable.
Growing Profit Margin: ALZ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALZ is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare ALZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ALZ has a negative Return on Equity (-14.47%), as it is currently unprofitable.